1h Free Analyst Time
The BCL-2 (B-Cell Lymphoma 2) inhibitors market is forecasted to grow by USD 2.28 billion during 2023-2028, accelerating at a CAGR of 15.2% during the forecast period. The report on the BCL-2 (B-Cell Lymphoma 2) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising geriatric population globally, growing awareness about hematological malignancies, and high target affinity and specificity of BCL-2 inhibitors.
The BCL-2 (B-Cell Lymphoma 2) inhibitors market is segmented as below:
By Product
- Combination therapy
- Monotherapy
By Type
- Diffuse large B-cell lymphoma (DLBCL)
- Follicular lymphoma
- Chronic lymphocytic leukemia
- Mantle cell lymphoma (MCL)
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the BCL-2 (B-Cell Lymphoma 2) inhibitors market covers the following areas:
- BCL-2 (B-Cell Lymphoma 2) inhibitors market sizing
- BCL-2 (B-Cell Lymphoma 2) inhibitors market forecast
- BCL-2 (B-Cell Lymphoma 2) inhibitors market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
360 degree market analysis
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global BCL-2 (B-Cell Lymphoma 2) inhibitors market: AbbVie Inc., Danaher Corp., Amgen Inc., Ascentage Pharma Group International, AstraZeneca PLC, BeiGene Ltd., Bio Techne Corp., Biorbyt Ltd., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Ipsen Pharma, Merck and Co. Inc., Novartis AG, Santa Cruz Biotechnology Inc., Seagen Inc., Les Laboratoires Servier, and Eli Lilly and Co..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increase in number of patient assistance programs."
According to the report, one of the major drivers for this market is the rising geriatric population globally.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Danaher Corp.
- Amgen Inc.
- Ascentage Pharma Group International
- AstraZeneca Plc
- BeiGene Ltd.
- Bio Techne Corp.
- Biorbyt Ltd.
- Bristol Myers Squibb Co.
- F. Hoffmann La Roche Ltd.
- Ipsen Pharma
- Merck and Co. Inc.
- Novartis AG
- Santa Cruz Biotechnology Inc.
- Seagen Inc.
- Les Laboratoires Servier
- Eli Lilly and Co.
